+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pheochromocytoma - Pipeline Review, H2 2019

  • ID: 4901386
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 105 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Enterome Bioscience SA
  • Exelixis Inc
  • Fujifilm Holdings Corp
  • Gibson Oncology LLC
  • Ipsen SA
  • Jubilant DraxImage Inc
  • MORE
Pheochromocytoma - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H2 2019, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 9, 2 and 2 respectively.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Enterome Bioscience SA
  • Exelixis Inc
  • Fujifilm Holdings Corp
  • Gibson Oncology LLC
  • Ipsen SA
  • Jubilant DraxImage Inc
  • MORE
Introduction
Report Coverage
Pheochromocytoma - Overview
Pheochromocytoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pheochromocytoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pheochromocytoma - Companies Involved in Therapeutics Development
Advanced Accelerator Applications SA
Enterome Bioscience SA
Exelixis Inc
Fujifilm Holdings Corp
Gibson Oncology LLC
Ipsen SA
Jubilant DraxImage Inc
Lixte Biotechnology Holdings Inc
Oncoceutics Inc
Pfizer Inc
Tarveda Therapeutics Inc
Pheochromocytoma - Drug Profiles
Pheochromocytoma - Dormant Projects
Pheochromocytoma - Discontinued Products
Pheochromocytoma - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Pheochromocytoma, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pheochromocytoma - Pipeline by Advanced Accelerator Applications SA, H2 2019
Pheochromocytoma - Pipeline by Enterome Bioscience SA, H2 2019
Pheochromocytoma - Pipeline by Exelixis Inc, H2 2019
Pheochromocytoma - Pipeline by Fujifilm Holdings Corp, H2 2019
Pheochromocytoma - Pipeline by Gibson Oncology LLC, H2 2019
Pheochromocytoma - Pipeline by Ipsen SA, H2 2019
Pheochromocytoma - Pipeline by Jubilant DraxImage Inc, H2 2019
Pheochromocytoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2019
Pheochromocytoma - Pipeline by Oncoceutics Inc, H2 2019
Pheochromocytoma - Pipeline by Pfizer Inc, H2 2019
Pheochromocytoma - Pipeline by Tarveda Therapeutics Inc, H2 2019
Pheochromocytoma - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Pheochromocytoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Advanced Accelerator Applications SA
  • Enterome Bioscience SA
  • Exelixis Inc
  • Fujifilm Holdings Corp
  • Gibson Oncology LLC
  • Ipsen SA
  • Jubilant DraxImage Inc
  • Lixte Biotechnology Holdings Inc
  • Oncoceutics Inc
  • Pfizer Inc
  • Tarveda Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll